ATLANTA, GA, MAY 11, 2022 – Radyus Research, a preclinical research organization, has appointed industry veteran Jane McCracken to its Board of Directors to help support Radyus’s rapid growth and expansion into European markets.
McCracken has over 25 years of experience on both sides of the Atlantic managing fast-growing entrepreneurial businesses in the technology, life sciences, and clinical research sectors to become successful operations.
McCracken previously served as CEO of an oncology focused CRO, which grew from a startup to a multinational firm acquired in 2012, now owned by Labcorp Drug Development. Most recently, she was an Entrepreneur in Residence at a startup incubator at the Georgia Institute of Technology, helping technology entrepreneurs launch and build successful companies.
“Jane is a start-up catalyst with an impressive track record in the CRO space, and we are thrilled to have her join our Board of Directors. Her wide-ranging experience, alongside her entrepreneurial mindset makes her an invaluable resource to our clients and management team as we continue to expand our business model.” - Paul Tebbey, Board member and co-founder of Radyus Research.
In addition to McCracken’s executive experience, she has served on several boards of public and private companies, as well as government-related and non-profit organizations.
“I watched Radyus Research evolve their methodologies and pipeline this past year, and I am honored to join their board. I admire Radyus Research’s collaborative approach toward developing life-saving solutions for many complex and pervasive illnesses and look forward to working alongside the team.” -Jane McCracken
McCracken, who holds a bachelor’s degree from Wake Forest University and a master’s from Georgia Tech, is a frequent speaker and panelist at conferences, companies, and universities, and is an active volunteer in her community.
McCracken’s appointment follows Radyus Research’s strong growth in recent months and business expansion to Europe and Asia/Pacific. The organization aims to grow its staff in Georgia to over 50 people in the next five years.
Radyus Research is a preclinical research organization that offers comprehensive drug development services. Working with biotech companies and venture funds to develop their preclinical assets to IND, we plan, project manage and execute experiments through our vast global network of labs. Our clients rely on us to increase their R&D bandwidth and accelerate drug development timelines. With over 150 years of combined work experience, the Radyus team has developed therapeutics in oncology, immunology, neuro/CNS, respiratory, metabolic, and infectious diseases.
Email us at support@radyusresearch.com to learn more.
